Epivax Oncology

company

About

Epivax Oncology is a providence, RI and NY-based precision cancer immunotherapy company.

  • 1 - 10

Details

Last Funding Type
Grant
Last Funding Money Raised
$324.98K
Industries
Biotechnology,Health Care,Hospital
Founded date
Jan 1, 2017
Number Of Employee
1 - 10
Operating Status
Active

EpiVax Oncology is a provider of a clinical research and development platform intended to offer various type of precision cancer immunotherapies. The company's platform are based on optimal neo-epitopes selected through its proprietary and validated, in-silico, predictive algorithms, enabling clients to address the unmet medical needs that are inadequately addressed by current cancer therapeutic approaches.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$1.52M
Epivax Oncology has raised a total of $1.52M in funding over 2 rounds. Their latest funding was raised on Jun 12, 2018 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 12, 2018 Series Unknown $1.20M 2 Detail
May 18, 2018 Grant $324.98K 1 National Institutes of Health Detail

Investors

Number of Lead Investors
Number of Investors
1
3
Epivax Oncology is funded by 3 investors. National Institutes of Health and Horatio Ventures NYC are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Grant
Horatio Ventures NYC Series Unknown
NextWaveBio Series Unknown